Research partially funded by the JKTG Foundation recently appeared recently in the journal ‘Cancers’.
The research, Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC, includes work by Daniele M. Gilkes, Ph.D., a researcher with whom JKTG has worked on several projects.
Initial JKTG funding connected researchers with highly experienced mentors to develop collaborative research projects via the Applied Mathematics in Germinating Oncology Solutions (AMIGOS) workshop resulting in Gilkes tracking individual cancer cells that experience hypoxia as they metastasize in a mouse model.
Her project collaborator, Paul Macklin, Ph.D., used this data to develop a mathematical model explaining how hypoxia promotes cell migration in a primary tumor.
The work highlighted in this most recent publication investigates whether cells that experienced intratumoral hypoxia are also resistant to chemotherapy.
By utilizing both in vivo and ex vivo models, the researchers conclude that metastatic cells found in the lung and liver, that were exposed to hypoxia in the primary tumor, are less sensitive to doxorubicin and paclitaxel and drive recurrence after treatment.
Our studies also suggest that chemoresistance is associated with a cancer stem cell-like phenotype that is maintained in post-hypoxic cells.
The Jayne Koskinas Ted Giovanis Foundation for Health and Policy (JKTG Foundation) today announced funding to develop a prototype multiscale model designed to predict therapeutic responses of tumor ecosystems – a new frontier in breast cancer research.
The word “stakeholder” really bothers me particularly in the healthcare space. I’m struck by a quote by Ken Burns.
“The thing that I’ve learned is that there is no ‘them.’ This is what everybody does: make a distinction about ‘them.’ It’s just ‘us’.”
In racing, we measure this in lap times often down to the second or tenths of a second. A recent racing article provoked me to think about the pursuit of “the last tenth” of a second in improvement which is typically the toughest and most difficult to attain.